|
1
|
Chen KW, Ou TM, Hsu CW, Horng CT, Lee CC,
Tsai YY, Tsai CC, Liou YS, Yang CC, Hsueh CW and Kuo WH: Current
systemic treatment of hepatocellular carcinoma: A review of the
literature. World J Hepatol. 7:1412–1420. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sinn DH, Lee J, Goo J, Kim K, Gwak GY,
Paik YH, Choi MS, Lee JH, Koh KC, Yoo BC and Paik SW:
Hepatocellular carcinoma risk in chronic hepatitis B virus-infected
compensated cirrhosis patients with low viral load. Hepatology.
62:694–701. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Debes JD, Chan AJ, Balderramo D, Kikuchi
L, Ballerga Gonzalez E, Prieto JE, Tapias M, Idrovo V, Davalos MB,
Cairo F, et al: Hepatocellular carcinoma in South America:
Evaluation of risk factors, demographics, and therapy. Liver Int.
38:136–143. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Petrick JL, Campbell PT, Koshiol J,
Thistle JE, Andreotti G, Beane-Freeman LE, Buring JE, Chan AT,
Chong DQ, Doody MM, et al: Abstract 3007: Tobacco smoking, alcohol
use and risk of hepatocellular carcinoma and intrahepatic
cholangiocarcinoma: The Liver Cancer Pooling Project. Cancer Res.
77:2017. View Article : Google Scholar
|
|
5
|
Zampino R, Pisaturo MA, Cirillo G, Marrone
A, Macera M, Rinaldi L, Stanzione M, Durante-Mangoni E, Gentile I,
Sagnelli E, et al: Hepatocellular carcinoma in chronic HBV-HCV
co-infection is correlated to fibrosis and disease duration. Ann
Hepatol. 14:75–82. 2015.PubMed/NCBI
|
|
6
|
Hamid AS, Tesfamariam IG, Zhang Y and
Zhang ZG: Aflatoxin B1-induced hepatocellular carcinoma in
developing countries: Geographical distribution, mechanism of
action and prevention. Oncol Lett. 5:1087–1092. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alavian SM and Haghbin H: Relative
Importance of Hepatitis B and C viruses in hepatocellular carcinoma
in EMRO countries and the Middle East: A systematic review. Hepat
Mon. 16:e351062016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Balan S, Finnigan J and Bhardwaj N:
Dendritic cell strategies for eliciting mutation-derived tumor
antigen responses in patients. Cancer J. 23:131–137. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu Y, Li L, Xiang X, Wang H, Cai W, Xie J,
Han Y, Bao S and Xie Q: Three common functional polymorphisms in
microRNA encoding genes in the susceptibility to hepatocellular
carcinoma: A systematic review and meta-analysis. Gene.
527:584–593. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lyragonzález I, Floresfong LE,
Gonzálezgarcía I, Medina-Preciado D and Armendáriz-Borunda J:
Adenoviral gene therapy in hepatocellular carcinoma: A review.
Hepatol Int. 7:48–58. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zekri AR, Sabry GM, Bahnassy AA, Shalaby
KA, Abdel-Wahabh SA and Zakaria S: Mismatch repair genes (hMLH1,
hPMS1, hPMS2, GTBP/hMSH6, hMSH2) in the pathogenesis of
hepatocellular carcinoma. World J Gastroenterol. 11:3020–3026.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zimonjic DB and Popescu NC: Role of DLC1
tumor suppressor gene and MYC oncogene in pathogenesis of human
hepatocellular carcinoma: Potential prospects for combined targeted
therapeutics (review). Int J Oncol. 41:393–406. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu X, Sun W, Tang Y, Zhu L, Li Y, Ou C,
Yang C, Su J, Luo C, Hu Y and Cao J: Identification of key genes in
hepatocellular carcinoma and validation of the candidate gene,
cdc25a, using gene set enrichment analysis, meta-analysis and
cross-species comparison. Mol Med Rep. 13:1172–1178. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kondo Y, Kanai Y, Sakamoto M, Mizokami M,
Ueda R and Hirohashi S: Genetic instability and aberrant DNA
methylation in chronic hepatitis and cirrhosis-A Comprehensive
Study of loss of heterozygosity and microsatellite instability at
39 Loci and DNA hypermethylation on 8 CpG islands in microdissected
specimens from patients with hepatocellular carcinoma. Hepatology.
32:970–979. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao RC, Zhou J, He JY, Wei YG, Qin Y and
Li B: Aberrant promoter methylation of SOCS-1 gene may contribute
to the pathogenesis of hepatocellular carcinoma: A meta-analysis. J
Buon. 21:142–151. 2016.PubMed/NCBI
|
|
16
|
Udali S, Guarini P, Ruzzenente A,
Ferrarini A, Guglielmi A, Lotto V, Tononi P, Pattini P, Moruzzi S,
Campagnaro T, et al: DNA methylation and gene expression profiles
show novel regulatory pathways in hepatocellular carcinoma. Clin
Epigenetics. 7:432015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zimmerli L, Hou BH, Tsai CH, Jakab G,
Mauch-Mani B and Somerville S: The xenobiotic beta-aminobutyric
acid enhances Arabidopsis thermotolerance. Plant J. 53:144–156.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tiezzi F, Parker-Gaddis KL, Cole JB, Clay
JS and Maltecca C: A genome-wide association study for clinical
mastitis in first parity US Holstein cows using single-step
approach and genomic matrix re-weighting procedure. PLoS One. 2015
Feb 6;10(2): e0114919 View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43:(Database Issue). D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jayachandran M: An updated portrait of
pathogenesis, molecular markers and signaling pathways of
hepatocellular carcinoma. Curr Pharm Design. 23:2356–2365. 2017.
View Article : Google Scholar
|
|
22
|
Liu Y, Yang Z, Du F, Yang Q, Hou J, Yan X,
Geng Y, Zhao Y and Wang H: Molecular mechanisms of pathogenesis in
hepatocellular carcinoma revealed by RNA-sequencing. Mol Med Rep.
16:6674–6682. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen J, Qian Z, Li F, Li J and Lu Y:
Integrative analysis of microarray data to reveal regulation
patterns in the pathogenesis of hepatocellular carcinoma. Gut
Liver. 11:112–120. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stegh AH: Targeting the p53 signaling
pathway in cancer therapy-the promises, challenges and perils.
Expert Opin Ther Targets. 16:67–83. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Grochola LF, Zeronmedina J, Mériaux S and
Bond GL: Single-nucleotide polymorphisms in the p53 signaling
pathway. Cold Spring Harb Perspect Biol. 2:a0010322010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kirstein MM and Vogel A: The pathogenesis
of hepatocellular carcinoma. Dig Dis. 32:545–553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang P, Cui J, Wen J, Guo Y, Zhang L and
Chen X: Cisplatin induces HepG2 cell cycle arrest through targeting
specific long noncoding RNAs and the p53 signaling pathway. Oncol
Lett. 12:4605–4612. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu W, Li X, Chu ES, Go MY, Xu L, Zhao G,
Li L, Dai N, Si J, Tao Q, et al: Paired box gene 5 is a novel tumor
suppressor in hepatocellular carcinoma through interaction with p53
signaling pathway. Hepatology. 53:843–853. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jin Y, Cao B, Zhang M, Zhan Q, Herman JG,
Yu M and Guo M: RASSF10 suppresses hepatocellular carcinoma growth
by activating P53 signaling and methylation of RASSF10 is a
docetaxel resistant marker. Genes Cancer. 6:231–240.
2015.PubMed/NCBI
|
|
30
|
Hong X, Liu PQ, Liang JX and Yun FU:
Genistein induces apoptosis through upregulation of p53 signaling
pathway. J Trop Med. 9:893–896, 910.
|
|
31
|
Lehtinen MK, Yuan Z, Boag PR, Yang Y,
Villén J, Becker EB, DiBacco S, de la Iglesia N, Gygi S, Blackwell
TK and Bonni A: A conserved MST-FOXO signaling pathway mediates
oxidative-stress responses and extends life span. Cell.
125:987–1001. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Da NI, Xue S, Lian F and Wang WJ:
Platelet-derived growth factor stimulates vascular smooth muscle
cell proliferation through AKT-FoxO signaling pathway. Mol Cardiol
China. 2011.
|
|
33
|
Huang P, Zhou Z, Wang H, Wei Q, Zhang L,
Zhou X, Hutz RJ and Shi F: Effect of the IGF-1/PTEN/Akt/FoxO
signaling pathway on the development and healing of water immersion
and restraint stress-induced gastric ulcers in rats. Int J Mol Med.
30:650–658. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hou YQ, Yao Y, Bao YL, Song ZB, Yang C,
Gao XL, Zhang WJ, Sun LG, Yu CL, Huang YX, et al: Juglanthraquinone
C induces intracellular ROS increase and apoptosis by activating
the Akt/Foxo signal pathway in HCC cells. Oxid Med Cell Longev.
2016:49416232016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang Z, Liu S, Zhu M, Zhang H, Wang J, Xu
Q, Lin K, Zhou X, Tao M, Li C and Zhu H: PS341 inhibits
hepatocellular and colorectal cancer cells through the FOXO3/CTNNB1
signaling pathway. Sci Rep. 6:220902016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sykes SM, Lane SW, Bullinger L,
Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H,
Brumme KM, et al: AKT/FOXO signaling enforces reversible
differentiation blockade in myeloid leukemias. Cell. 146:697–708.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lu M, Hu XH, Li Q, Xiong Y, Hu GJ, Xu JJ,
Zhao XN, Wei XX, Chang CC, Liu YK, et al: A specific cholesterol
metabolic pathway is established in a subset of HCCs for tumor
growth. J Mol Cell Biol. 5:404–415. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Björnsson E: The differential rank
conservation algorithm (DIRAC) reveals deregulation of central
metabolic pathways in hepatocellular carcinoma. 2014.
|
|
39
|
Song B, Wang Y, Titmus MA, Botchkina G,
Formentini A, Kornmann M and Ju J: Molecular mechanism of
chemoresistance by miR-215 in osteosarcoma and colon cancer cells.
Mol Cancer. 9:962010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kawaguchi T, Komatsu S, Ichikawa D,
Hirajima S, Kosuga T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K
and Otsuji E: Overexpression of denticleless E3 ubiquitin protein
ligase homolog (DTL) is related to tumor cell proliferation and
malignant outcome in esophageal squamous cell carcinoma. J Am Coll
Surgeons. 221 Suppl 2:e132–e133. 2015. View Article : Google Scholar
|
|
41
|
Kobayashi H, Komatsu S, Ichikawa D,
Kawaguchi T, Hirajima S, Miyamae M, Okajima W, Ohashi T, Kosuga T,
Konishi H, et al: Overexpression of denticleless E3 ubiquitin
protein ligase homolog (DTL) is related to poor outcome in gastric
carcinoma. Oncotarget. 6:36615–36624. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gang L, Qun L, Liu WD, Li YS, Xu YZ and
Yuan DT: MicroRNA-34a promotes cell cycle arrest and apoptosis and
suppresses cell adhesion by targeting DUSP1 in osteosarcoma. Am J
Transl Res. 9:5388–5399. 2017.PubMed/NCBI
|
|
43
|
Kato I, Maita H, Takahashi-Niki K, Saito
Y, Noguchi N, Iguchi-Ariga SM and Ariga H: Oxidized DJ-1 inhibits
p53 by sequestering p53 from promoters in a DNA-binding
affinity-dependent manner. Mol Cell Biol. 33:340–359. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hao PP, Li H, Lee MJ, Wang YP, Kim JH, Yu
GR, Lee SY, Leem SH, Jang KY and Kim DG: Disruption of a regulatory
loop between DUSP1 and p53 contributes to hepatocellular carcinoma
development and progression. J Hepatol. 62:1278–1286. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wei X, Tang C, Lu X, Liu R, Zhou M, He D,
Zheng D, Sun C and Wu Z: MiR-101 targets DUSP1 to regulate the
TGF-β secretion in sorafenib inhibits macrophage-induced growth of
hepatocarcinoma. Oncotarget. 6:18389–18405. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ramos-Marquès E, Zambrano S, Tiérrez A,
Bianchi ME, Agresti A and García-Del Portillo F: Single-cell
analyses reveal an attenuated NF-κB response in the
Salmonella-infected fibroblast. Virulence. 8:719–740. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cheng CW, Su JL, Lin CW, Su CW, Shih CH,
Yang SF and Chien MH: Effects of NFKB1 and NFKBIA gene
polymorphisms on hepatocellular carcinoma susceptibility and
clinicopathological features. PLoS One. 8:e561302013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang WJ, Ren G, Qi JD, Liu SH and Liang J:
Expression changes of NFKBIA in hepatocellular carcinoma and its
significance. Shandong Medical Journal. 22:16–19. 2015.
|
|
49
|
Gao J, Xu HL, Gao S, Zhang W, Tan YT,
Rothman N, Purdue M, Gao YT, Zheng W, Shu XO and Xiang YB: Genetic
polymorphism of NFKB1 and NFKBIA genes and liver cancer risk: A
nested case-control study in Shanghai, China. BMJ Open.
4:e0044272014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cui M, Ji S, Hou J, Fang T, Wang X, Ge C,
Zhao F, Chen T, Xie H, Cui Y, et al: The suppressor of cytokine
signaling 2 (SOCS2) inhibits tumor metastasis in hepatocellular
carcinoma. Tumour Biol. 37:13521–13531. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Qiu X, Zheng J, Guo X, Gao X, Liu H, Tu Y
and Zhang Y: Reduced expression of SOCS2 and SOCS6 in
hepatocellular carcinoma correlates with aggressive tumor
progression and poor prognosis. Mol Cell Biochem. 378:99–106. 2013.
View Article : Google Scholar : PubMed/NCBI
|
